Graves’ Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Graves’ Ophthalmopathy Pipeline Drugs Market Report Overview

Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves‘ ophthalmopathy. Symptoms include eye redness, inflammation, eyelid retraction, and weakness. Treatment includes radioiodine therapy, anti-thyroid medications, and thyroid surgery.

The Graves’ Opththalmopathy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Graves’ Opththalmopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Graves’ Opththalmopathy and features dormant and discontinued projects.

Graves’ Opththalmopathy Pipeline Drugs Market Segmentation by Targets

The key targets in the Graves’ Opththalmopathy pipeline drugs market are Insulin Like Growth Factor 1 Receptor, IgG Receptor FcRn Large Subunit p51, Interleukin 17A, Glucocorticoid Receptor, and others.  Insulin Like Growth Factor 1 Receptor has the highest number of products in development in the Graves’ Opththalmopathy pipeline drugs market in 2022.

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Targets

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by TargetsFor more target insights into the Graves’ Opththalmopathy pipeline drugs market, download a free report sample

Graves’ Opththalmopathy Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Graves’ Opththalmopathy pipeline drugs market are Insulin Like Growth Factor 1 Receptor Antagonist, Insulin Like Growth Factor 1 Receptor Inhibitor, IgG Receptor FcRn Large Subunit p51 Antagonist, Interleukin 17A Inhibitor, and others. Insulin Like Growth Factor 1 Receptor Antagonist leads the Graves’ Opththalmopathy pipeline drugs market in terms of MoA.

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Mechanisms of Action

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Mechanisms of ActionFor more MoA insights into the Graves’ Opththalmopathy pipeline drugs market, download a free report sample

Graves’ Opththalmopathy Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Graves’ Opththalmopathy pipeline drugs market are subcutaneous, intravenous, intramuscular, intravenous drip, and others. The subcutaneous RoA has the highest number of Graves’ Opththalmopathy drugs in development in 2022.

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Routes of Administration

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Routes of AdministrationFor more RoA insights into the Graves’ Opththalmopathy pipeline drugs market, download a free report sample

Graves’ Opththalmopathy Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Graves’ Opththalmopathy pipeline drugs market are monoclonal antibody, biologic, fusion protein, small molecule, and synthetic peptide. Monoclonal antibody leads the Graves’ Opththalmopathy pipeline drugs market in terms of molecule type.

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Molecule Types

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Molecule TypesFor more molecule type insights into the Graves’ Opththalmopathy drugs market, download a free report sample

Graves’ Opththalmopathy Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Graves’ Opththalmopathy pipeline drugs market are Genmab AS, Viridian Therapeutics Inc, HanAll Biopharma Co Ltd, and ImmunoGen Inc. Genmab AS and Viridian Therapeutics Inc accounted for the highest number of Graves’ Opththalmopathy drugs in development in 2022.

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Companies

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by CompaniesTo know more about the leading Graves’ Opththalmopathy pipeline drugs market players, download a free report sample

Graves’ Opththalmopathy Pipeline Products Market Overview

Key Targets Insulin Like Growth Factor 1 Receptor, IgG Receptor FcRn Large Subunit p51, Interleukin 17A, Glucocorticoid Receptor, and Others
Key Mechanisms of Action Insulin Like Growth Factor 1 Receptor Antagonist, Insulin Like Growth Factor 1 Receptor Inhibitor, IgG Receptor FcRn Large Subunit p51 Antagonist, Interleukin 17A Inhibitor, and Others
Key Routes of Administration Subcutaneous, Intravenous, Intramuscular, Intravenous Drip, and Others
Key Molecule Type Monoclonal Antibody, Biologic, Fusion Protein, Small Molecule, and Synthetic Peptide
Leading Companies Genmab AS, Viridian Therapeutics Inc, HanAll Biopharma Co Ltd, ImmunoGen Inc, and Others

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Graves’ Opththalmopathy.
  • The pipeline guide reviews pipeline therapeutics for Graves’ Opththalmopathy by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Graves’ Opththalmopathy therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Graves’ Opththalmopathy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Graves’ Opththalmopathy

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Graves’ Opththalmopathy.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the Graves’ Opththalmopathy pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

advanceCor GmbH
Enceladus Pharmaceuticals BV
Eye Bio Korea Co Ltd
Genmab AS
GSK plc
HanAll Biopharma Co Ltd
ImmunoGen Inc
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Novartis AG
Pierre Fabre Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
RevOpsis Therapeutics Corp
Sling Therapeutics Inc
Suzhou Pulekang Pharmaceutical Technology Co Ltd
Viridian Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Graves’ Ophthalmopathy – Overview

Graves’ Ophthalmopathy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Graves’ Ophthalmopathy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Graves’ Ophthalmopathy – Companies Involved in Therapeutics Development

Graves’ Ophthalmopathy – Drug Profiles

Graves’ Ophthalmopathy – Dormant Projects

Graves’ Ophthalmopathy – Discontinued Products

Graves’ Ophthalmopathy – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Graves’ Ophthalmopathy, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Graves’ Ophthalmopathy – Pipeline by advanceCor GmbH, 2022

Graves’ Ophthalmopathy – Pipeline by Enceladus Pharmaceuticals BV, 2022

Graves’ Ophthalmopathy – Pipeline by Eye Bio Korea Co Ltd, 2022

Graves’ Ophthalmopathy – Pipeline by Genmab AS, 2022

Graves’ Ophthalmopathy – Pipeline by GSK plc, 2022

Graves’ Ophthalmopathy – Pipeline by HanAll Biopharma Co Ltd, 2022

Graves’ Ophthalmopathy – Pipeline by ImmunoGen Inc, 2022

Graves’ Ophthalmopathy – Pipeline by Innovent Biologics Inc, 2022

Graves’ Ophthalmopathy – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Graves’ Ophthalmopathy – Pipeline by Novartis AG, 2022

Graves’ Ophthalmopathy – Pipeline by Pierre Fabre Pharmaceuticals Inc, 2022

Graves’ Ophthalmopathy – Pipeline by Regeneron Pharmaceuticals Inc, 2022

Graves’ Ophthalmopathy – Pipeline by RevOpsis Therapeutics Corp, 2022

Graves’ Ophthalmopathy – Pipeline by Sling Therapeutics Inc, 2022

Graves’ Ophthalmopathy – Pipeline by Suzhou Pulekang Pharmaceutical Technology Co Ltd, 2022

Graves’ Ophthalmopathy – Pipeline by Viridian Therapeutics Inc, 2022

Graves’ Ophthalmopathy – Dormant Projects, 2022

Figures

List of Figures

Number of Products under Development for Graves’ Ophthalmopathy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Graves’ Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Graves’ Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Graves’ Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Graves’ Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.